Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK/PD of HIP1601 vs HGP1705 in Healthy Male Volunteers
NCT03372850Phase 1Unknown
- Sponsor
- Hanmi Pharmaceutical
- Start
- Feb 2018
- Primary completion
- Jun 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of esomeprazole strontium in gastroesophageal reflux disease (GERD) and erosive esophagitis (EE) (2 arms), sponsored by Hanmi Pharmaceutical. Primary endpoints: Area Under the Concentration-Time Curve from Time Zero to Last Quantifiable Concentration at Day 7 and Total Gastric Acidity Decrease Rate Versus Baseline at Day 7. Status: unknown.
02
Drugs
esomeprazole strontium
03
Conditions
gastroesophageal reflux disease (GERD)erosive esophagitis (EE)
Beyond the preview
Go deeper on NCT03372850.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03372850.